Latest News and Press Releases

IRVING, Texas, March 30, 2026 (GLOBE NEWSWIRE) -- XBP Global Holdings, Inc. (“XBP Global” or “the Company”) (NASDAQ: XBP), a multinational technology and services company orchestrating...

Completed strategic acquisition of dual-targeting CAR-T assets from Factor Bioscience Inc. Named Matt Angel, Ph.D., Chief Executive Officer & President Announced positive interim data from the...

First patient dosed in UPSTREAM SjD, a global Phase 3 clinical trial assessing telitacicept in primary Sjögren’s disease $75 million private placement strengthens balance sheet and supports...

HANGZHOU, China, March 30, 2026 (GLOBE NEWSWIRE) -- Nano Labs Ltd (Nasdaq: NA) (“we,” the “Company” or “Nano Labs”), a leading Web 3.0 infrastructure and product solution provider and crypto...

Reports $46.8M Revenue for 2025 materially ahead of market expectations Exits 2025 at $232M ARR1 with $19.4M December MRR1 Contracted Revenue1 Underpins 2026 Growth Trajectory FY 2026 revenue...

Signed First Binding Customer Offtake Agreement with TrafiguraReceived Indications of Interest for Over $1 Billion in Project FinanceProvides an Update on Plans for a Final Investment Decision (“FID”)...

Eikon Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Clinical and Corporate Updates

MediPharm Labs, today announced its financial results for the full year and three months ended December 31st, 2025.

Selected 1500mg weekly of ficerafusp alfa as the optimal dose and initiated Phase 3 of the FORTIFI-HN01 pivotal trial; interim analysis expected mid-2027 Announced development of a less frequent...

Oxylanthanum carbonate (OLC) New Drug Application (NDA) resubmission under review by U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) target action date of June...